Tags : $292.5M

Biotech M&A

Charles River to Acquire Vigene Biosciences for $292.5M

Shots: Charles River Laboratories to acquire Vigene in all cash transaction for $292.5M. In addition to the initial purchase price, the transaction includes contingent additional payments of up to $57.5M based on future performance The transaction is expected to be close in Q3’21. The acquisition will allow Charles River to boost its gene therapy capabilities […]Read More